First tested in 2007, the Yars missile system has a potential range of up to 12 thousand kilometers and can carry six to 10 independently targetable warheads.

亚尔斯导弹系统于 2007 年首次测试，其潜在射程可达 1.2 万公里，可携带 6 至 10 枚独立的目标弹头。

So this idea that no matter where you're sharing it, to what group chat, to whatever communication tool that you're using, remember they own WhatsApp as well, it's completely simple and for advertisers, highly targetable.

因此，这种理念是， 无论你在何处分享内容，无论是哪个群聊， 还是你使用的任何通讯工具，记住他们也拥有WhatsApp，这一切都变得极为简便， 并且于广告商来说，具有高度。

Molecular testing for targetable gene mutations is critical for treatment selection (see Chapter 7).

靶向基因突变的分子检测于治疗选择至关重要（参见第 7 章）。

The best strategy for patients with unresectable stage III NSCLC who harbor targetable mutations such as alterations in the EGFR gene also needs further investigation.

于携带 EGFR 基因改变等靶向突变的不可切除的 III 期 NSCLC 患者，最佳策略也需要进一步研究。

For rarer targetable genetic alterations in ROS1, RET and MET, a similar approach is often used.

于 ROS1、RET 和 MET 中较罕见的可靶向遗传改变，通常使用类似的方法。

Unlike other targetable oncogene drivers in NSCLC, KRAs G12C is most common in smokers Until recently, KRAS was an undruggable target.

与 NSCLC 中的其他靶向癌基因驱动因素不同，KRA G12C 在吸烟者中最常见。直到最近，KRAS 仍是一个不可药物治疗的靶点。

Many are now targetable, but not all targeted therapies have been approved (Figure 7.2).

现在许多靶向疗法都是可靶向的，但并非所有靶向疗法都已获得批准（图 7.2）。

The majority of patients without a targetable molecular alteration receive immunotherapy-based treatment as first-line therapy, either as a single agent in tumors expressing high levels of PD-L1 or in combination with chemotherapy.

大多数没有靶向分子改变的患者接受基于免疫治疗的治疗作为一线治疗，或者作为表达高水平 PD-L1 的肿瘤的单一药物，或者与化疗相结合。

Most targetable mutations occur in the adenocarcinoma subtype of NSCLC.

大多数靶向突变发生在 NSCLC 的腺癌亚型中。

The successful application of checkpoint inhibitors in metastatic NSCLC without targetable mutations (see Chapter 6) has inspired ongoing efforts to incorporate the same strategy into the treatment of early-stage disease.

检查点抑制剂在无靶向突变的转移非小细胞肺癌中的成功应用（见第6章）激发了人们不断努力将相同的策略纳入早期疾病的治疗中。

A proportion of patients with NSCLC will have somatic genetic alterations that can be targeted by specific molecular compounds, with the list of such 'targetable' mutations growing constantly (see Chapter 7).

一部分非小细胞肺癌患者将出现可被特定分子化合物靶向的体细胞遗传改变，此类“可靶向”突变的列表不断增长（见第 7 章）。